Selected Milestones & Industry defining events:

February 2007, Dr. Low incorporates NeuroVigil.
March 2008, Medicare approved reimbursement for home testing.
May 2008, Winner, DFJ Venture Challenge and UCSD Venture Challenge 3 days later.
June 2008, NeuroVigil scientists publish in PNAS (journal with 5th highest impact factor).
June 2008, first iBrain Prototype (incl. analog part, A/D, firmware) successfully tested in humans.
February 2009, License Agreement with Salk institute – grants exclusivity of use of Dr. Low’s patent.
October 2009, Contract with Roche, Swiss Pharma with >100B market cap, to use iBrain & analysis.
October 2009, NeuroVigil introduces Wireless iBrain Cell Phone at TedMed.
Q4 2009, NeuroVigil breaks cash-flow positive for the first time.
December 2009, Frontiers in Neuroscience article about NeuroVigil.
February 2010, NeuroVigil hosts 1st Intl. Conf on Alzheimer’s Dis. and Advanced Neurotech in Monaco.
August 2010, NeuroVigil CEO on MIT list of World’s Top Young Innovators.
October 2010, Human Trials begin.
November 2010, Lead story about NeuroVigil and Dr. Low by NBC.
December 2010, NeuroVigil and Stanford announce research partnership in the field of Autism.
December 2010, NeuroVigil’s iBrain wins CONNECT’S Most Innovative New Product Award in Life Sciences, Diagnostics and Research tools.
December 2010, Forbes and BILAN, Swiss business magazine, publish articles about NeuroVigil and iBrain.
March 2011, NeuroVigil listed by Fast Company as one of the Top 10 Most Innovative Companies in Health Care, alongside GE & Cleveland Clinic.
May 2011, NeuroVigil closes first round of financing.
June 2011, NeuroVigil CEO wins inaugural Jacobs-Rady Pioneer Award for Global Innovation and Entrepreneurship.
June 2011, US Military does successful test with NeuroVigil Technology.
June 2011, Stephen Hawking starts using NeuroVigil Technology.
July 2011, NeuroVigil featured in Washington Post.
August 2011, NeuroVigil pinpoints early indication of drug biomarker in a clinical trial.
August 2011, USPTO approves the iBrain trademark for both medical and consumer devices.
November 2011, Stephen Hawking joins NeuroVigil.
December 2011, NeuroVigil successfully defends Dr. Low’s initial patent in front of the USPTO.
January 2012, NeuroVigil files patent on Neural Correlates of Intent.
January 2012, NeuroVigil proposes a new Alzheimer’s Initiative to expedite treatment of Mild Cognitive Impairment/Alzheimer patients to White House.
April 2012, New York Times Story on iBrain, generates over 60 media articles, including in TIME, in over 25 countries in over 21 languages and spreads virally.
May 2012, ALS Clinical Trial in partnership with ALS Hope Foundation and Drexel University begins.
June 2012, iBrain is a New York Times’ “Innovation that Will Change Your Tomorrow”.
January 2013, Dr. Low singled out by The Scientist as “Scientist to Watch”.
April 2013, Dr. Low invited to White House twice, including for BRAIN Initiative Announcement.
May 21st 2013, Individual with ALS spells word, untrained, using single channel non-invasive NeuroVigil technology.
June 2013, Core Patent granted in China.
July 2013, New York Times Story and Discovery Channel Show with Morgan Freeman on NeuroVigil.
August 2013, Patent-pending iBrain III project, a silver dollar sized wireless consumer device, launched.
August 2013, Master Agreement closed with Novartis.
September 2013, Core Patent granted in Israel.
August 2013, Novartis backed biomarker deal closed.
October 2013, Patent-Pending Algorithm for Arousals with high sensitivity and specificity is completed.
October 2013, Israel Brain Conference keynote.
May 2014, Core Patent granted in South Korea.
September 2014, Master Agreement closed with Simmons, NeuroVigil retains all data, all biomarkers and IP rights from the use of its technology.
October 2014, Core Patent granted in Canada.
October 2014, discussions with NASA regarding sending technology to International Space Station begin.
January 2015, NeuroVigil & the American Senior Housing Association (ASHA) Announce Landmark Neurotechnology Alliance to Monitor the Aging Brain. Contracts to be signed with individual ASHA units.
January 2015, NeuroVigil signs brain monitoring Master Agreement with an ASHA member, a Senior Living community, with the goal of servicing all residents.
April 2015, Core Patent granted in EU.
April 2015, NeuroVigil CEO gives Annual Keynote for School of Bioengineering at UCSD’s Jacobs School of Engineering.
April 2015, NeuroVigil closes second round of financing.
May 2015, Hardware patent issued in New Zealand.
April 2015, August 2015, Hardware patent issued in Japan.
September 2015, Sleep biomarkers patent issued in Israel.
September 2015, NeuroVigil CEO participates at Waterloo Innovation Summit & begins discussion with Blackberry CEO.
October 2015, NeuroVigil begins discussion with Jewish Home of San Francisco to provide brain monitoring services.
October 2015, USPTO notifies NeuroVigil that it will allow its detection of Intent patent.
January 2016, NeuroVigil & T.A. Sciences sign letter of intent.
March 2016, NeuroVigil & Simmons sign senior care study Letter of Intent for 10M iBrains.
April 2016, Feature story on NeuroVigil in Newsweek
Summer 2016, Israel, China, Hong Kong, Japan award SPEARS, sleep biomarkers and iBrain patents
November 2016, NeuroVigil is approached by two senior care communities in Canada for brain activity monitoring services there.
February 2017, iBrain 3 in prototype stage.
November 2017, Forbes publishes story on NeuroVigil.
Summer 2018, Wyoming Governor and Department of Health sign MOU with NeuroVigil to have access to innovations from its planned accelerator.
Summer 2018-Summer 2019, City of San Diego approves accelerator, ongoing discussions with Argentina, Canada, Chile, Germany, Mexico, Portugal and UK to amplify accelerator. Domestic and International startups apply to join accelerator, including MIT wearables spin-off, FDA approved TMS company and in vitro drug testing company, wearables company and neuro-oncology company.